Isolation of Human Endothelial Cells from Normal Colon and Colorectal Carcinoma - An Improved Protocol
April 4th, 2018
18.4K views
Tumor endothelial cells are important determinants of the tumor microenvironment and the course of the disease. Here, a protocol for the isolation of pure and viable endothelial cells from human colorectal carcinoma and normal colon to be used in drug testing and pathogenesis research is described.
Overview
This article presents a protocol for isolating pure and viable endothelial cells from human colorectal carcinoma and normal colon tissues. The method aims to facilitate drug testing and research into the pathogenesis of colorectal cancer.
Key Study Components
Area of Science
- Neuroscience
- Cell Biology
- Oncology
Background
- Tumor endothelial cells significantly influence the tumor microenvironment.
- Understanding these cells can provide insights into tumor biology and angiogenesis.
- Isolating viable endothelial cells is crucial for studying colorectal carcinoma.
- This protocol aims to enhance the success rate of obtaining these cells from patients.
Purpose of Study
- To isolate endothelial cells from colorectal carcinoma and normal colon tissues.
- To analyze the role of the blood vessel system in colorectal tumorigenesis.
- To provide a reliable method for drug testing and pathogenesis research.
Methods Used
- Collection of tissue specimens from colorectal carcinoma patients.
- Sequential washing and processing of tissue samples.
- Dissociation of minced tissue using a tissue dissociator.
- FACS sorting to identify and isolate viable endothelial cells.
Main Results
- Successful isolation of tumor and normal endothelial cells.
- Identification of cell populations through FACS analysis.
- Immunocytochemistry confirmed the expression of endothelial cell markers.
- Yield of 3.6% tumor and 5.6% normal endothelial cells from the total population.
Conclusions
- The protocol effectively isolates viable endothelial cells for research.
- Insights gained can advance understanding of colorectal cancer biology.
- This method can be applied to further studies in tumor angiogenesis.
Frequently Asked Questions
What is the significance of endothelial cells in tumors?
Endothelial cells play a crucial role in forming blood vessels that supply nutrients to tumors, influencing tumor growth and metastasis.
How does this protocol improve cell isolation?
The protocol enhances the success rate of isolating pure and viable endothelial cells from colorectal carcinoma tissues.
What are the applications of isolated endothelial cells?
Isolated endothelial cells can be used for drug testing, studying tumor biology, and understanding angiogenesis in cancer.
What techniques are used to analyze the isolated cells?
FACS analysis and immunocytochemistry are employed to identify and characterize the endothelial cells.
What challenges are associated with isolating these cells?
Challenges include ensuring the purity of the cell population and preventing cell death or senescence during culture.
How can this research impact cancer treatment?
By understanding the role of endothelial cells in tumors, researchers can develop targeted therapies that disrupt tumor blood supply.
Executive Industry Relevance
Reliable isolation of pure, viable human endothelial cells from both normal colon and colorectal carcinoma tissue enables mechanistic interrogation of the tumor microenvironment and vascular contributions to tumorigenesis. This protocol supports predictive confidence in early discovery and target validation by providing disease-relevant cellular models for functional studies and therapeutic hypothesis testing. The approach enhances portfolio decision-making by enabling robust evaluation of anti-angiogenic strategies and resistance mechanisms in colorectal cancer.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct study of tumor endothelial cell (TEC) biology and their role in the tumor microenvironment.
- Supports functional validation of vascular targets implicated in colorectal cancer progression and therapy response.
- Facilitates mechanistic de-risking by distinguishing TECs from normal endothelial cells (NECs) using marker-based FACS sorting.
- Provides a platform for evaluating the impact of specific microenvironmental factors on endothelial phenotype and function.
Screening & Assay Development
- Delivers pure, viable primary TEC and NEC cultures suitable for downstream compound screening and assay development.
- Enables quantitative assessment of endothelial cell marker expression and functional outputs via immunocytochemistry and RT-qPCR.
- Improves assay reproducibility and standardization by ensuring high-purity cell populations through triple-marker FACS sorting.
- Supports screening of anti-angiogenic agents in a disease-relevant cellular context.
Translational & Preclinical Research
- Aligns in vitro endothelial models with patient-derived tumor biology for translational biomarker discovery.
- Enables investigation of TEC memory-like effects and their contribution to the tumor microenvironment.
- Facilitates studies on resistance mechanisms to anti-angiogenic therapies using primary human cells.
- Supports risk-adjusted advancement of vascular-targeted therapeutics in preclinical pipelines.
Pipeline & Workflow Integration
This protocol integrates into the discovery-to-preclinical continuum by providing validated primary endothelial cell cultures for mechanistic studies, assay development, and translational research in colorectal cancer.
- Discovery Biology: Supports hypothesis testing on vascular contributions to tumorigenesis and therapy response.
- Screening: Provides standardized, high-purity cell populations for reproducible compound evaluation.
- Analytics: Enables quantitative measurement of endothelial markers and functional outputs for comparative studies.
- Translational Research: Bridges in vitro findings with patient-derived tumor biology for biomarker alignment.
- Enterprise Reuse: Establishes a reusable workflow for isolating primary endothelial cells from diverse tissue sources.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in vascular target validation and mechanistic studies.
- Operational Value: Standardizes isolation and characterization of primary endothelial cells for scalable R&D workflows.
- Strategic Value: Enables informed go/no-go decisions for anti-angiogenic and microenvironment-targeted therapies.
- Portfolio Impact: Supports risk-adjusted prioritization of vascular-targeted assets in oncology pipelines.
Implementation Considerations
- Requires expertise in primary endothelial cell culture and FACS-based cell sorting.
- Demands access to fresh human tissue specimens and coordination with surgical and pathology teams.
- Necessitates specialized instrumentation for tissue dissociation, FACS analysis, and quantitative molecular assays.
- Involves cross-team standardization of tissue processing and cell characterization protocols.
- Practical limitations include cell fragility, timing of cell splitting, and potential for fibroblast overgrowth if not carefully managed.
Biopharma FAQs
Why does null hypothesis testing matter for TEC marker validation?
Null hypothesis testing ensures that observed differences in endothelial marker expression between tumor and normal cells are statistically significant, supporting robust target validation and reducing false positives in early discovery.
How does FACS-based triple-marker isolation fit the discovery pipeline?
FACS-based isolation of CD31, VE-cadherin, and CD105 triple-positive cells enables precise separation of TECs and NECs, providing high-purity populations for downstream mechanistic and screening studies in the discovery workflow.
What do quantitative RT-qPCR measurements of endothelial markers enable?
Quantitative RT-qPCR of endothelial markers allows for objective assessment of cell purity and phenotype, enabling reliable comparison across experimental conditions and supporting assay development and validation.
Why are replication requirements critical for cross-functional TEC studies?
Replication ensures that isolation and characterization of TECs yield consistent results across samples and operators, facilitating cross-functional collaboration and reproducibility in multi-site R&D programs.
What statistical analysis capabilities are needed before TEC implementation?
Robust statistical analysis is required to validate cell purity, marker expression, and functional outputs, ensuring that TEC-derived data meet enterprise standards for decision-making and pipeline advancement.
Chapters in this video
0:04
Title
0:51
Surgery, Preparation of Tissue, and Generation of Single Cell Suspension
4:17
FACS Sorting, Harvesting and Characterization of Endothelial Cells
7:17
Results: Isolation of Normal and Tumor Endothelial Cells via FACS Sorting and Study of Endothelial Cell Specific Markers
8:59
Conclusion
